Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. SABCS 2019.
Phase 1: Final Analysis of ELACESTRANT in ER+/HER2- Advanced Breast Cancer
December 12, 2019